Immune Pharmaceuticals (IMNP) Earning Somewhat Favorable News Coverage, Analysis Finds
Media headlines about Immune Pharmaceuticals (NASDAQ:IMNP) have trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.0642738023857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Immune Pharmaceuticals (IMNP) vs. Its Rivals Financial Contrast (americanbankingnews.com)
- Head to Head Contrast: Immune Pharmaceuticals (IMNP) & Its Competitors (americanbankingnews.com)
- Does Immune Pharmaceuticals Inc’s (IMNP) Past Performance Indicate A Stronger Future? (finance.yahoo.com)
- Immune Provides Corporate Update Regarding Executive Officers (di.se)
- Wired News – Pfizer Announced an Agreement to Develop and Commercialize Basilea’s Antifungal CRESEMBA in China and the Asia/ Pacific Region (finance.yahoo.com)
Immune Pharmaceuticals (NASDAQ:IMNP) opened at $0.83 on Monday. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of 3.04. Immune Pharmaceuticals has a one year low of $0.76 and a one year high of $5.02.
COPYRIGHT VIOLATION NOTICE: “Immune Pharmaceuticals (IMNP) Earning Somewhat Favorable News Coverage, Analysis Finds” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/11/immune-pharmaceuticals-imnp-earning-somewhat-favorable-news-coverage-analysis-finds.html.
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Stock Ratings for Immune Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.